6855 — Ascentage Pharma International Share News
0.000.00%
Last trade - 00:00- HK$11.38bn
- HK$11.63bn
- CNY574.12m
Brief: Ascentage Pharma Group International Says CDE Of NMPA Approved Clinical Study Of Class 1 Novel MDM2-P53 Inhibitor APG-115
Brief: Ascentage Pharma Group International Enters Agreement With University Of Michigan
Brief: Ascentage Pharma Group Says APG-2575 Receives Approvals For Two Phase Ib/II Clinical Studies In China
Brief: Ascentage Pharma Group International Says Its APG-115 Granted Approval For Phase Ib/Ii Clinical Study In China
Brief: Ascentage Pharma Group International Says Olverembatinib Gets Approval From NMPA
Brief: Ascentage Pharma Group International Says APG-115 And APG-1252 Granted Orphan Drug Designation By US FDA
Brief: Ascentage Pharma's Apoptosis-Targeting Drug Candidates Granted Two More Orphan Drug Designations By The Us FDA
Brief: Ascentage Pharma's MDM2-P53 Inhibitor APG-115 Granted Orphan Drug Designation By The FDA For The Treatment Of Gastric Cancer
Brief: Ascentage Pharma Group International Says U.S. FDA Granted APG- 115 An Orphan Drug Designation
Brief: Ascentage Pharma Group International Says APG-2575 Granted Second Orphan Drug Designation By US FDA
Brief: Ascentage Pharma Group International Posts HY Loss Attributable RMB 319.2 MLN
HK-listed Ascentage Pharma falls on discounted share sale
Brief: Ascentage Pharma Group International To Issue Placing Shares
Brief: Ascentage Pharma Group International Says Co Entered Clinical Collaboration
Brief: Ascentage Pharma Enters Clinical Collaboration With Acerta Pharma
Brief: Ascentage Pharma Group International Says USFDA Granted Hqp1351 Fast Track Designation
Brief: Ascentage Pharma's Core Drug Candidate HQP1351 Granted Fast Track Designation By FDA
Brief: Ascentage Pharma Group International Says U.S. FDA Grants HQP1351 Orphan Drug Designation
Brief: Ascentage Pharma Group International Says Co Received Nod In U.S & China For Phase Ib/Ii Clinical Trials Of APG-2575